医薬品・バイオテクノロジー・医療機器・診断における資産購入取引 (2016～2024年)

当レポートでは、企業が事業・製品・技術・ロイヤルティ等の資産購入取引に参入する方法と理由を詳細に理解・分析することができます。

当レポートは、当事者間で発表された資産購入案件の支払条件へのアクセスを提供します。このデータは、支払い条件やその他の取引条件について有益な洞察を提供します。

当レポートでは、購入可能な主な4種類の資産に焦点を当てています：

• 事業資産
• 製品資産
• ロイヤルティ資産
• 技術資産
• パートナー候補が交渉した取引条件の柔軟性を理解し、条件交渉中に何を期待できるかについて、交渉プロセスに対する重要な洞察が得られます。多くの中小企業は支払い条項の詳細を求めるでしょうが、支払いがどのように発生し、権利がどのように譲渡されるかという点では、細部が肝要となります。
• 当レポートでは、2016年以降に発表された資産購入案件について、Current Agreementsの案件・提携データベースに記録されているものを包括的にリストアップしています。

主な利点

当レポートでは、読者に以下の主な利点を提供します：

• 2016年以降の取引締結動向の把握
• 資産購入取引の閲覧
• ベンチマーク分析：取引の市場価値を特定
• 財務条件
• 取引一覧：企業名別 (A～Z)、治療領域別、技術の種類別
• 主要な取引 (金額ベース)
• 最も活発な取引業者
• 各取引の資産・取引条件の特定
• 契約文書へのアクセス：取引構造に関する洞察
• デューデリジェンス：提案された取引条件のパートナー企業への適合性を評価
• 数百時間の調査時間を節約

調査範囲

• 当レポートは、世界の主要バイオ医薬品企業による資産購入の動向と取引構造を詳細に理解することを目的としています。

当レポートには以下の情報が含まれます：

• ライフサイエンス業界における資産購入取引の動向
• 資産購入の取引構造：概要
• 医薬品・バイオテクノロジー・医療機器・診断を対象とした資産購入取引記録の一覧
• 主要な資産購入取引 (金額ベース)
• 最も活発な資産購入取引の取引業者
• 資産購入の主要な提携リソース

当レポートでは、情報が入手可能な取引案件を以下の順番でリストアップしています：

• 企業名別 (A～Z)
• 取引総額別
• 治療分野別
• 技術の種類別
• 各取引タイトルは、Webリンクを通じて実際の取引記録のオンライン版にリンクしています。
• 当レポートは、資産購入取引に関する利用可能な契約文書への包括的なアクセスを提供します。

契約合意を分析することで、以下のデューデリジェンスが可能になります：

• どのような権利が付与・選択されているのか？
• 契約によってどのような権利が付与されるか？
• どのような独占権が付与されているか。
• 契約の支払い構造は？
• 販売・支払はどのように監査されるか？
• 契約期間は？
• 契約の主要条件はどのように定義されるか？
• 知的財産権はどのように扱われ、所有されるのか？
• 商業化の責任者は誰か？
• 開発・供給・製造の責任者は誰か？
• 秘密保持と公表はどのように管理されるか？
• 紛争はどのように解決されるのか？
• どのような条件で契約を解除することができるのか？
• 所有者が変わった場合はどうなるのか？
• どのようなサブライセンス条項や下請け条項が合意されているか？
• 企業はどの定型条項を要求しているか？
• どの定型条項が、パートナーや案件の種類によっては、異なるように見えるか？
• 各企業は、契約法についてどの管轄権を主張しているか？

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 資産購入の動向

• イントロダクション
• 資産購入の定義
• 資産購入の動向 (2016年以降)
  • 資産購入の取引締結：年別 (2016～2024年)
  • 資産購入の取引締結：開発段階別 (2016～2024年)
  • 資産購入の取引締結：業種別 (2016～2024年)
  • 資産購入の取引締結：治療領域別 (2016～2024年)
  • 資産購入の取引締結：技術の種類別 (2016～2024年)
  • 資産購入の取引締結：最も活発な企業の場合 (2016～2024年)
• 資産購入契約を締結する理由
  • 事業資産
  • 製品資産
  • ロイヤルティ資産
  • テクノロジー資産
• 今後の資産購入取引

第3章 資産購入取引構造の概要

• イントロダクション
• 資産購入の構造

第4章 主要な資産購入取引

• イントロダクション
• 主な資産購入取引 (金額ベース)

第5章 最も活発な資産購入の取引業者上位25社

• イントロダクション
• 最も活発な資産購入の取引業者 (取引締結企業) 上位25社

第6章 資産購入取引の一覧 (契約内訳を含む)

• イントロダクション
• 資産購入取引の契約 (2016～2024年)
• 取引一覧
• 取引一覧：資産購入の取引締結、企業名別 (A～Z)
• 取引一覧：資産購入の取引締結、治療領域別
• 取引一覧：資産購入の取引締結、技術の種類別
• Biopharma Research Ltdについて
• 現在の提携
• 現在の契約
• Current Partnering刊行の最近のレポートタイトル

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

• Business assets
• Product assets
• Royalty assets
• Technology assets
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of asset purchase deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
• Chapter 3 provides an overview of the structure of asset purchase deals.
• Chapter 4 provides a review of the leading asset purchase deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
• Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
• The deal directory includes a comprehensive listing of all asset purchase deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
• The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2016.
• In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.

Key benefits

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse asset purchase deals
• Benchmark analysis - identify market value of transactions
• Financials - headline, upfront, milestone, royalty rates
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics includes:

• Trends in asset purchase dealmaking in the life sciences industry
• Overview of asset purchase deal structure
• Directory of asset purchase deal records covering pharmaceuticals, biotechnology, medical devices and diagnostics
• The leading asset purchase deals by value
• Most active asset purchase dealmakers
• The leading asset purchase partnering resources

In Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via hyperlink to an online version of the actual deal record, providing easy access to each contract document where available.
• Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides comprehensive access to available records for asset purchase deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

• 2.1. Introduction
• 2.2. Types of assets purchased
• 2.3. Trends in asset purchase deals since 2016
  • 2.3.1. Asset purchase dealmaking by year, 2016-2024
  • 2.3.2. Asset purchase dealmaking by phase of development, 2016-2024
  • 2.3.3. Asset purchase dealmaking by industry sector, 2016-2024
  • 2.3.4. Asset purchase dealmaking by therapy area, 2016-2024
  • 2.3.5. Asset purchase dealmaking by technology type, 2016-2024
  • 2.3.6. Asset purchase dealmaking by most active company, 2016-2024
• 2.4. Reasons for entering into asset purchase partnering deals
  • 2.4.1. Business assets
  • 2.4.2. Product assets
  • 2.4.3. Royalty assets
  • 2.4.4. Technology assets
• 2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

• 3.1. Introduction
• 3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

• 4.1. Introduction
• 4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

• 6.1. Introduction
• 6.2. Asset purchase deals with contracts 2016-2024
• Deal directory
• Deal directory - Asset purchase dealmaking by companies A-Z
• Deal directory - Asset purchase dealmaking by therapy area
• Deal directory - Asset purchase dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of assets purchased
• Figure 2: Trends in asset purchase deal announcements, 2016-2024
• Figure 3: Asset purchase deals signed at each phase of development, 2016-2024
• Figure 4: Asset purchase deals by industry sector, 2016-2024
• Figure 5: Asset purchase deals by therapy area, 2016-2024
• Figure 6: Asset purchase deals by technology type, 2016-2024
• Figure 7: Top 25 most active asset purchase dealmakers, 2016-2024
• Figure 8: Top asset purchase deals by value, 2016-2024
• Figure 9: Most active asset purchase dealmakers, 2016-2024